US FDA publishes guidance on CLIA waivers
This article was originally published in Clinica
The US FDA has published revised guidance for device manufacturers seeking to get their products waived from regulatory oversight under the Clinical Laboratory and Improvement Amendments of 1988 (CLIA) law. In the regulations published to implement the CLIA in 1992, waived tests were defined as simple laboratory examinations and procedures that were cleared by the FDA for home use, or that employ methodologies that -are simple and accurate as to render the likelihood of erroneous result negligible", or that pose no reasonable risk of harm to the patient if the test is performed incorrectly.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.